Orphazyme

About:

Orphazyme develops innovative new therapies for the treatment of a family of serious genetic disorders called lysosomal storage diseases.

Website: http://www.orphazyme.com/

Twitter/X: orphazyme_aps

Top Investors: Novo Holdings, Wellcome Trust, EQT Life Sciences, Kurma Partners, Idinvest Partners

Description:

Orphazyme develops innovative new therapies for the treatment of a family of serious genetic disordes called lysosomal storage diseases, and is based on discoveries emerging from the academic laboratory of its scientific founders: Professor Marja Jäättela and Thomas Kirkegaard Jensen from the Danish Cancer Society (Kræftens Bekæmpelse). Orphazyme is based in Copenhagen and has established collaborations with top-tier academic institutions in Europe and USA.